Status:

COMPLETED

Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)

Lead Sponsor:

AstraZeneca

Collaborating Sponsors:

Bristol-Myers Squibb

Conditions:

Type 2 Diabetes Mellitus

Eligibility:

All Genders

18-65 years

Phase:

PHASE1

Brief Summary

It is anticipated that 7 days of oral administration of 10 mg dapagliflozin will reduce the renal glucose reabsorption similarly in healthy subjects and in subjects with T2DM.

Eligibility Criteria

Inclusion

  • Inclusion criteria for T2DM
  • Diagnosis of T2DM
  • Must be on one of the following therapies: diet therapy alone, diet plus a sulfonylurea, diet plus metformin, or diet plus sulfonylurea plus metformin
  • Subjects taking metformin, and/or sulfonylurea must be on a stable dose for at least 2 months prior to study drug administration
  • Must have a fasting plasma glucose concentration ≤ 200 mg/dl, and HbA1C ≤ 10%
  • Inclusion criteria for healthy subjects:
  • Healthy subjects (as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations)
  • Inclusion criteria for all subjects:
  • Subjects with (eGFR ≥ 60 and ≤ 160 mL/min/1.73m² and urinary albumin excretion \< 300 mg/g creatinine)
  • Body Mass Index (BMI) of 18 to 38 kg/m²
  • Men and women, ages 18 to 65 years, inclusive
  • Exclusion criteria for all subjects:
  • Subjects with Type 1 Diabetes or uncontrolled Type 2 Diabetes Mellitus
  • Subjects with T2DM with fasting plasma glucose \> 200 mg/dL, healthy subjects with fasting plasma glucose \> 105 mg/dL
  • Subjects with T2DM with HbA1C \> 10.0%, healthy subjects with HbA1C \> 6.8%

Exclusion

    Key Trial Info

    Start Date :

    August 1 2010

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    December 1 2010

    Estimated Enrollment :

    24 Patients enrolled

    Trial Details

    Trial ID

    NCT01165268

    Start Date

    August 1 2010

    End Date

    December 1 2010

    Last Update

    November 17 2016

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Profil Institute For Clinical Research, Inc.

    Chula Vista, California, United States, 91911